{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:02:55Z","timestamp":1792414975786,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100002641","name":"Konkuk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecules and Cells"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.14348\/molcells.2023.2188","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T04:42:46Z","timestamp":1684903366000},"page":"420-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Bcl-2\/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-1803","authenticated-orcid":false,"given":"Wonseon","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-8366","authenticated-orcid":false,"given":"Chul-Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-9087","authenticated-orcid":false,"given":"Junghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-4754","authenticated-orcid":false,"given":"Hyungwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-6406","authenticated-orcid":false,"given":"Hyewon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14348\/molcells.2023.2188_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"7","author":"Arepalli","year":"2021","journal-title":"Int. J. Retina Vitreous"},{"key":"10.14348\/molcells.2023.2188_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev."},{"key":"10.14348\/molcells.2023.2188_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.14348\/molcells.2023.2188_bib4","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s11357-021-00457-4","article-title":"Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration","volume":"43","author":"Chae","year":"2021","journal-title":"Geroscience"},{"key":"10.14348\/molcells.2023.2188_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm.4010","article-title":"Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice","volume":"22","author":"Chang","year":"2016","journal-title":"Nat. Med."},{"key":"10.14348\/molcells.2023.2188_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1124\/mi.10.5.4","article-title":"Age-related macular degeneration: genetic and environmental factors of disease","volume":"10","author":"Chen","year":"2010","journal-title":"Mol. Interv."},{"key":"10.14348\/molcells.2023.2188_bib7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4000","article-title":"Cellular senescence in aging and age-related disease: from mechanisms to therapy","volume":"21","author":"Childs","year":"2015","journal-title":"Nat. Med."},{"key":"10.14348\/molcells.2023.2188_bib8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.14348\/molcells.2023.2188_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","volume":"10","author":"Cox","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.14348\/molcells.2023.2188_bib10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2021.01.011","article-title":"Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition","volume":"33","author":"Crespo-Garcia","year":"2021","journal-title":"Cell Metab."},{"key":"10.14348\/molcells.2023.2188_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","article-title":"Cellular senescence in ageing: from mechanisms to therapeutic opportunities","volume":"22","author":"Di Micco","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.14348\/molcells.2023.2188_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","article-title":"Molecular pathology of age-related macular degeneration","volume":"28","author":"Ding","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.14348\/molcells.2023.2188_bib13","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.3390\/cancers12123688","article-title":"Lamin A\/C: function in normal and tumor cells","volume":"12","author":"Dubik","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.14348\/molcells.2023.2188_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond.)"},{"key":"10.14348\/molcells.2023.2188_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.14348\/molcells.2023.2188_bib16","doi-asserted-by":"crossref","first-page":"1212369","DOI":"10.1155\/2019\/1212369","article-title":"Drugs and clinical approaches targeting the antiapoptotic protein: a review","volume":"2019","author":"Han","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.14348\/molcells.2023.2188_bib17","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration","volume":"10","author":"Handa","year":"2019","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.2188_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","article-title":"Cellular senescence: the good, the bad and the unknown","volume":"18","author":"Huang","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.14348\/molcells.2023.2188_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.14348\/molcells.2021.2239","article-title":"Transcriptomic analysis of cellular senescence: one step closer to senescence atlas","volume":"44","author":"Kim","year":"2021","journal-title":"Mol. Cells"},{"key":"10.14348\/molcells.2023.2188_bib20","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.14348\/molcells.2023.2188_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exger.2014.10.012","article-title":"Clinical strategies and animal models for developing senolytic agents","volume":"68","author":"Kirkland","year":"2015","journal-title":"Exp. Gerontol."},{"key":"10.14348\/molcells.2023.2188_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.mehy.2012.01.018","article-title":"RPE cell senescence: a key contributor to age-related macular degeneration","volume":"78","author":"Kozlowski","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.14348\/molcells.2023.2188_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.14348\/molcells.2022.0084","article-title":"Cellular senescence: the villain of metabolic disease?","volume":"45","author":"Lee","year":"2022","journal-title":"Mol. Cells"},{"key":"10.14348\/molcells.2023.2188_bib24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.14348\/molcells.2023.2188_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.2188_bib26","doi-asserted-by":"crossref","first-page":"564108","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.14348\/molcells.2023.2188_bib27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.2188_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41591-018-0141-4","article-title":"Targeting senescence","volume":"24","author":"Serrano","year":"2018","journal-title":"Nat. Med."},{"key":"10.14348\/molcells.2023.2188_bib29","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Shoemaker","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.2188_bib30","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.14348\/molcells.2023.2188_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","article-title":"Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study","volume":"62","author":"de Vos","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.14348\/molcells.2023.2188_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.V110.11.1371.1371","article-title":"A Phase 1\/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies","volume":"110","author":"Wilson","year":"2007","journal-title":"Blood"},{"key":"10.14348\/molcells.2023.2188_bib33","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"}],"container-title":["Molecules and Cells"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-07-04.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-07-04.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T17:56:37Z","timestamp":1760896597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1016847823000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1016847823000511"],"URL":"https:\/\/doi.org\/10.14348\/molcells.2023.2188","relation":{},"ISSN":["1016-8478"],"issn-type":[{"value":"1016-8478","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Bcl-2\/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells","name":"articletitle","label":"Article Title"},{"value":"Molecules and Cells","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14348\/molcells.2023.2188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of the Korean Society for Molecular and Cellular Biology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}